TY - JOUR
T1 - Multiple Myeloma, Version 2.2024
AU - Kumar, Shaji K.
AU - Callander, Natalie S.
AU - Adekola, Kehinde
AU - Anderson, Larry D.
AU - Baljevic, Muhamed
AU - Baz, Rachid
AU - Campagnaro, Erica
AU - Castillo, Jorge J.
AU - Costello, Caitlin
AU - D’Angelo, Christopher
AU - Devarakonda, Srinivas
AU - Elsedawy, Noura
AU - Garfall, Alfred
AU - Godby, Kelly
AU - Hillengass, Jens
AU - Holmberg, Leona
AU - Htut, Myo
AU - Huff, Carol Ann
AU - Hultcrantz, Malin
AU - Kang, Yubin
AU - Larson, Sarah
AU - Lee, Hans C.
AU - Liedtke, Michaela
AU - Martin, Thomas
AU - Omel, James
AU - Robinson, Timothy
AU - Rosenberg, Aaron
AU - Sborov, Douglas
AU - Schroeder, Mark A.
AU - Sherbenou, Daniel
AU - Suvannasankha, Attaya
AU - Valent, Jason
AU - Varshavsky-Yanovsky, Asya Nina
AU - Kumar, Rashmi
AU - Snedeker, Jenna
N1 - Publisher Copyright:
© 2023, National Comprehensive Cancer Network® (NCCN®)
PY - 2023/12
Y1 - 2023/12
N2 - The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These include new combinations with second generation proteasome inhibitors (PI) second generation immunomodulators, monoclonal antibodies, CAR T cells, bispecific antibodies, selinexor, venetoclax, and many others. Most patients with MM undergo several cycles of remissions and relapse, and therefore need multiple lines of combination therapies. Selecting treatment options for relapsed/refractory MM requires consideration of resistance status to specific classes, and patient-specific factors such as age and other comorbidities should be considered. The NCCN Guidelines for MM provide a framework on which to base decisions regarding workup, treatment, and follow-up of newly diagnosed and previously treated MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to relapsed/refractory disease.
AB - The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These include new combinations with second generation proteasome inhibitors (PI) second generation immunomodulators, monoclonal antibodies, CAR T cells, bispecific antibodies, selinexor, venetoclax, and many others. Most patients with MM undergo several cycles of remissions and relapse, and therefore need multiple lines of combination therapies. Selecting treatment options for relapsed/refractory MM requires consideration of resistance status to specific classes, and patient-specific factors such as age and other comorbidities should be considered. The NCCN Guidelines for MM provide a framework on which to base decisions regarding workup, treatment, and follow-up of newly diagnosed and previously treated MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to relapsed/refractory disease.
UR - http://www.scopus.com/inward/record.url?scp=85179646486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85179646486&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2023.0061
DO - 10.6004/jnccn.2023.0061
M3 - Article
C2 - 38081133
AN - SCOPUS:85179646486
SN - 1540-1405
VL - 21
SP - 1281
EP - 1301
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 12
ER -